Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|CALGB-40302||CALGB||Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized; Double-Blind; Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041202||Alliance||A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACNS1123||COG||Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT): A Groupwide Phase II Study||Pediatric CIRB||Available to Open|
|A211601||Alliance||Evaluation of Mammographic Breast Density Effect of Aspirin: A companion study to Alliance Study A011502||Cancer Prevention and Control CIRB||Available to Open|
|10186||ETCTN||A Phase I/II Study of Nivolumab plus or minus Ipilimumab in Combination with Multi-fraction Stereotactic Radiosurgery for Recurrent High-grade Radiation-relapsed Meningioma||Adult CIRB - Early Phase Emphasis||Available to Open|
|EA5163||ECOG-ACRIN||INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis||Adult CIRB - Late Phase Emphasis||Available to Open|
|AHOD0831||COG||A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|ANBL0531||COG||Response- and Biology-Based Therapy for Intermediate-risk Neuroblastoma: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|AALL1732||COG||A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy||Pediatric CIRB||Available to Open|
|AAML1331||COG||A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid: A COG Groupwide Phase III Study||Pediatric CIRB||Available to Open|